Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant: Staphylococcus aureus

Drugs in R and D

Volumn 8, Issue 2, 2007, Pages 69-77

  Su, Young Lee ^a   Hong, Wei Fan ^a   Sutherland, Christina ^a   DeRyke, Andrew C ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; IN VITRO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; CULTURE MEDIA; EPITHELIUM; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES; STAPHYLOCOCCUS AUREUS;

EID: 33847352470     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708020-00001     Document Type: Article

References (27)

1. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33
2. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
3. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84
4. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005; 6: 283-95
5. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: emertations gence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819-24
6. Martinez-Aguilar G, Hammerman WA, Mason EO, et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22: 593-8
7. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9
8. Bradley SF. Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 2005; 26: 643-9
9. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-7
10. Abi-Hanna P, Frank AL, Quinn JP, et al. Clonal features of community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis 2000; 30: 630-1
11. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21: 530-4
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S16. Wayne (PA): Clinical Laboratory Standards Institute: 2006
13. Florea NR, Tessier PR, Zhang C, et al. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48: 1215-21
14. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004; 125: 965-73
15. Onyeji CO, Bui KQ, Owens RC, et al. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicemia. Int J Antimicrob Agents 1999; 12: 107-14
16. Firsov AA, Vostrov SN, Kononenko OV, et al. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 1999; 43: 498-502
17. Yamagishi J, Kojima T, Oyamada Y, et al. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1157-63
18. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1554-8
19. Horii T, Suzuki Y, Monji A, et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003; 46: 139-45
20. Noguchi N, Okihara T, Namiki Y, et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25: 374-9
21. Craig WA, Andes DR, Ambrose PG, et al. In vivo pharmacodynamic activity of gatifloxacin, levofloxacin, and moxifloxacin against Staphylococcus aureus with reduced susceptibility to fluoroquinolones (abstract). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005 Dec 16-19; Washington, DC:
22. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-44
23. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-8
24. MacDougall C, Powell JP, Johnson CK, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435-40
25. Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006; 42: 778-84
26. Firsov AA, Vostrov SN, Lubenko IY, et al. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents 2004; 23: 451-6
27. Schrenzel J, Harbarth S, Schockmel G, et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004; 39: 1285-92